Positive early results for Boehringer Ingelheim’s investigational antidote idarucizumab

19 November 2014

The US subsidiary of German family-owned pharma major Boehringer Ingelheim has presented Phase I study sub-analyses showing that its investigational antidote idarucizumab reverses the effects of Pradaxa (dabigatran etexilate mesylate), on fibrin formation in healthy volunteers.

The results showed idarucizumab, a humanized antibody fragment (Fab), restores wound-site formation of fibrin, the main component of a blood clot. The findings were presented today during the American Heart Association’s Scientific Sessions 2014.

“These data are the first to show idarucizumab restores dabigatran-induced inhibition of wound-site fibrin formation,” said Joanne van Ryn, Department of CardioMetabolic Disease Research, at Boehringer Ingelheim, Germany. “The findings from this sub-analysis complement earlier findings which showed that idarucizumab provides immediate, complete and sustained reversal of the anticoagulation effects of dabigatran,” he added.

Study details

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK